Hearing News Watch

Featured image for “Bilateral Gene Therapy Trial Successfully Restores Hearing in Five Children”
Jun. 06, 2024

Bilateral Gene Therapy Trial Successfully Restores Hearing in Five Children

HHTM
BOSTON, MASSACHUSSETTS — A groundbreaking clinical trial conducted in Shanghai, China, in collaboration with researchers from Mass Eye and Ear, has demonstrated significant advancements in the treatment of autosomal recessive deafness caused by mutations in the OTOF gene. This novel gene therapy, administered to both ears of five children, successfully restored their hearing and provided additional benefits such as improved
Featured image for “Cilcare and Shionogi Announce Exclusive Option Agreement to Develop Hearing Loss Treatments”
Jun. 06, 2024

Cilcare and Shionogi Announce Exclusive Option Agreement to Develop Hearing Loss Treatments

HHTM
OSAKA & MONTPELLIER – Shionogi & Co., Ltd. and Cilcare have announced an exclusive option agreement to advance the development of innovative treatments for hearing loss. This collaboration grants Shionogi the rights to develop, manufacture, and commercialize Cilcare’s drug candidates, CIL001 and CIL003, aimed at addressing the significant global health issue of hearing loss. Under the terms of the agreement:
Featured image for “Successful Advocacy by Maryland Audiologists Modernizes Practice Act”
Jun. 01, 2024

Successful Advocacy by Maryland Audiologists Modernizes Practice Act

HHTM
ANNAPOLIS, MARYLAND — On May 29, 2024, Maryland enacted SB 795 and HB 464, aligning its audiology practice act with the education, training, and qualifications of audiologists practicing in the state. Drs. Jana Brown, Briana Bruno Holtan, Melissa Segev, and Alicia Spoor, members of the Maryland Academy of Audiology (MAA), spearheaded the initiative. They drafted the legislation, provided testimony, and
Featured image for “Apple Hearing Study Unveils New Insights on Tinnitus in Landmark Survey”
May. 28, 2024

Apple Hearing Study Unveils New Insights on Tinnitus in Landmark Survey

HHTM
Apple, in collaboration with the University of Michigan, has released groundbreaking findings from the Apple Hearing Study, shedding light on tinnitus in one of the largest surveys to date. The study, which reviewed responses from over 160,000 participants, aims to improve the understanding of tinnitus characteristics and inform future research on potential treatments. Prevalence and Impact of Tinnitus The study’s
Featured image for “New Study: Hearing Loss Increases Risk of Cognitive Impairment, Dementia, and Alzheimer’s Disease”
May. 27, 2024

New Study: Hearing Loss Increases Risk of Cognitive Impairment, Dementia, and Alzheimer’s Disease

HHTM
A new systematic review and meta-analysis published in Ageing Research Reviews examined the relationship between adult-onset hearing loss and cognitive impairment. Analyzing data from fifty cohort studies involving over 1.5 million participants, the study suggests that hearing loss significantly increases the risk of cognitive decline, dementia, and Alzheimer’s disease (AD). Hearing loss is a major global health issue affecting an
Featured image for “New Study Highlights Tamiflu as a Promising Otoprotective Drug”
May. 25, 2024

New Study Highlights Tamiflu as a Promising Otoprotective Drug

HHTM
In a recent pre-print study posted on bioRxiv, researchers have identified oseltamivir, commonly known by its brand name Tamiflu®, as a potential otoprotective therapeutic candidate. The study highlights oseltamivir’s protective effects against hearing loss induced by both cisplatin chemotherapy and traumatic noise exposure. Currently, sodium thiosulfate (STS) is the only FDA-approved drug available to prevent hearing loss, specifically for use
Featured image for “Study Reveals High Incidence of Vestibular Impairment in Children with Profound Hearing Loss, Impacting Development”
May. 24, 2024

Study Reveals High Incidence of Vestibular Impairment in Children with Profound Hearing Loss, Impacting Development

HHTM
A recent cohort study published today in JAMA Network Open has revealed significant findings on the prevalence of vestibular impairment in children with bilateral profound hearing loss (HL) and its association with developmental delays. Conducted by Dr. Sylvette R. Wiener-Vacher and her colleagues at a pediatric referral center in Paris, France, the study underscores the critical need for comprehensive vestibular
Featured image for “Cilcare Appoints Dr. Naimi Missoum as Chief Medical Officer”
May. 23, 2024

Cilcare Appoints Dr. Naimi Missoum as Chief Medical Officer

HHTM
MONTPELLIER, FRANCE – Cilcare, a clinical-stage biotechnology company specializing in auditory sciences and the development of novel therapies for inner ear diseases, has announced the appointment of Dr. Naimi Missoum as Chief Medical Officer. Dr. Missoum, a Medical Doctor with over 25 years of experience as a senior executive in medical affairs at leading pharmaceutical companies, will oversee all of
Featured image for “Ear Science Institute Australia Secures Funding to Develop Australasian Biobank for Genetic Hearing Loss”
May. 22, 2024

Ear Science Institute Australia Secures Funding to Develop Australasian Biobank for Genetic Hearing Loss

HHTM
Ear Science Institute Australia has secured Future Health Research & Innovation (FHRI) funding to establish a Western Australia-headquartered Australasian biobank, aimed at advancing genetic therapies for childhood and adult hearing loss. The Australasian Hearing Registry and Biobank (AHRB) will be the first in Australia to store tissue related to genetic-associated hearing loss, with the goal of advancing personalized care and
Featured image for “Sound Pharmaceuticals Receives FDA Clearance for Phase 2 Trial of SPI-1005 in Cochlear Implant Patients”
May. 20, 2024

Sound Pharmaceuticals Receives FDA Clearance for Phase 2 Trial of SPI-1005 in Cochlear Implant Patients

HHTM
SEATTLE & INNSBRUCK, AUSTRIA — Sound Pharmaceuticals (SPI) has announced that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI). The goal of this Phase 2 SPI-1005 (ebselen) trial is to reduce the loss of residual hearing during and after CI. Ebselen is a novel anti-inflammatory compound that